Class action lawsuits
Alto Neuroscience, Inc. Faces Class Action Lawsuit Over Alleged Misleading Statements
Alto Neuroscience, Inc.'s initial public offering (IPO) in February 2024 was touted as a promising step forward in the treatment of major depressive disorder (MDD), with its flagship candidate, ALTO-100, set to undergo a Phase 2b clinical trial. However, a class action lawsuit filed on behalf of investors